Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Classic BS Basher article so shorts can recover shares on all Franks works.
NEWS -- Heat Biologics Announces Addition of Former US Senator Mark Pryor to Biothreat Advisory Board
DURHAM, N.C., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, announces the addition of Mark Pryor, former US Senator from the State of Arkansas, to the Company’s Biothreat Advisory Board.
Former US Senator Mark Pryor currently serves with the premier law firm, Brownstein Hyatt Farber Schreck. He is a former two-term U.S. senator and Arkansas attorney general. During his 12 years representing Arkansas in the Senate, he worked across the aisle to pass more than 70 pieces of legislation on a range of critical issues, including homeland security and defense. Sen. Pryor served on several high-profile committees during his tenure, including Appropriations; Armed Services; Commerce, Science and Transportation; Homeland Security and Governmental Affairs.
Jeff Wolf, Chief Executive Officer of Heat, commented, “As a leader on the Armed Services as well as the Homeland Security and Governmental Affairs committees, Senator Pryor brings unique expertise in policy and government affairs to our biothreat efforts. We look forward to leveraging Senator Pryor’s knowledge as we advance our new biothreat initiatives.”
Senator Pryor joins David Lasseter, Former Deputy Assistant Secretary of Defense for Countering Weapons of Mass Destruction; Former US Representative Jack Kingston, who also serves as the Secretariat of the Alliance for Biosecurity; Andrew C. Weber, Former Assistant Secretary of Defense for Nuclear, Chemical & Biological Defense Programs; and Dr. Gregory Koblentz, Associate Professor at George Mason University and leading expert on chemical and biological weapons.
About Heat Biologics, Inc.
Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. Heat’s gp96 platform is designed to activate immune responses against cancer or infectious diseases. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in a Phase 2 trial, various infectious disease/biological threat programs in preclinical development and a pipeline of proprietary immunomodulatory antibodies and cell-based therapies, including PTX-35 and HS-130 in Phase 1 clinical trials.
For more information, please visit: https://www.heatbio.com, and also follow us on Twitter.
Forward Looking Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 on our current expectations and projections about future events. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectation, and assumptions and include statements regarding the contributions to be made by Mark Pryor the advisory board and leveraging Senator Pryor’s knowledge as Heat advances its new biothreat initiatives. These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, including the ability of Heat to successfully develop a new biosecurity/biodefense initiative and benefit from the contributions of the advisory board, the ability of Heat's therapies to perform as designed, to demonstrate safety and efficacy, as well as results that are consistent with prior results, the ability to enroll patients and complete the clinical trials on time and achieve desired results and benefits, especially in light of COVID-19, Heat's ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to Heat's ability to promote or commercialize its product candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, Heat's ability to maintain its license agreements, the continued maintenance and growth of its patent estate, its ability to establish and maintain collaborations, its ability to obtain or maintain the capital or grants necessary to fund its research and development activities and its cash and short-term investments providing significant runway to fund Heat’s current clinical programs and further expand Heat’s therapeutic portfolio , its ability to continue to maintain its listing on the Nasdaq Capital Market and its ability to retain its key scientists or management personnel, and the other factors described in Heat's annual report on Form 10-K for the year ended December 31, 2020 filed with the SEC, and other subsequent filings with the SEC. The information in this release is provided only as of the date of this release, and Heat undertakes no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.
Media and Investor Relations Contact
David Waldman
+1 919 289 4017
mailto://investorrelations@heatbio.com
NEWS -- Plus Therapeutics Announces Presentation of Data from the ReSPECT™-GBM Trial and Plans for Treating Pediatric Brain Cancer
I didn't see any pump Press releases yet , the company has a low share floating and entering into the electric car market , this has a dollar written all over it plus I like the free shares of DRNG when you buy NIHK shares . Plus The CEO is a very intelligent fellow on the level of another Musk.
maybe ?
RDGL website looks updated ! https://www.radiogel.com/isopet/
https://www.radiogel.com/radiogel/
The new NIHK website is eminent , I bought 100,000 shares of NIHK today and 100,000 shares of DRNG today so I will get a total of 210,000 shares of DRNG after the Dividend , any investor should Buy NIHK and DRNG before the dividend date ends.
Also, our new CEO does cancel shares and also he doesn't like reverse splits he states never RS in any of his companies so that 100 billion possible shares could be eliminated when we become pink current.
Thanks for the clarification on the date I will get the shares . This has dollars written all over it .
Frank I. Igwealor said in a tweet, We're also working on a name change from Video River Networks. We need a name befitting a technology holding firm that operates a portfolio of Electric Vehicles, Artificial Intelligence, Machine Learning, and Robotics
I think VNTH technology will be used in the AI , machine learning, and Robotics subsidiaries .
PR, please !!!
I bought 100,000 shares Today of NIHK so now I will get 100,000 free shares of DRNG Drone Guard on September 1.
The new name change of Video River Networks Inc is the key for the new website to open. EV AI and ROBOTIC , to find a name that will attract new investors plus show what the company has .
NEWS -- Heat Biologics Announces New Additions to Biothreat Advisory Board
DURHAM, N.C., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, announces the following additions to its newly formed Biothreat Advisory Board: Andrew C. Weber, Former Assistant Secretary of Defense for Nuclear, Chemical & Biological Defense Programs; and Dr. Gregory Koblentz, Associate Professor at George Mason University and leading expert on chemical and biological weapons. These individuals join David Lasseter, Former Deputy Assistant Secretary of Defense for Countering Weapons of Mass Destruction, and Former US Representative Jack Kingston, who also serves as the Secretariat of the Alliance for Biosecurity.
Jeff Wolf, Chief Executive Officer of Heat, commented, “We are delighted to announce the addition of these highly renowned individuals in the fields of biosecurity and biodefense to our biothreat advisory board. As the former Assistant Secretary of Defense for Nuclear, Chemical and Biological Defense Programs, Mr. Weber has deep insight into the potential threats facing our nation and best potential avenues for developing effective solutions. Professor Koblentz is one of the leading global thought leaders in the field of chemical and biological weapons.”
Andy Weber is a Senior Fellow at the Council on Strategic Risks’ Janne E. Nolan Center on Strategic Weapons. He is also a member of the Council on Foreign Relations. Mr. Weber has dedicated his professional life to countering nuclear, chemical, and biological threats and to strengthening global health security. Mr. Weber’s decades of U.S. government service included five-and-a-half years as the Assistant Secretary of Defense for Nuclear, Chemical and Biological Defense Programs. He was a driving force behind reducing biological weapons threats, and destroying Libyan and Syrian chemical weapons stockpiles. In addition, he coordinated U.S. leadership of the international Ebola response for the Department of State.
Dr. Gregory D. Koblentz is an Associate Professor and Director of the Biodefense Graduate Program at George Mason University's Schar School of Policy and Government. He is also an Associate Faculty at the Center for Security Policy Studies at George Mason and a member of the Scientists Working Group on Chemical and Biological Security at the Center for Arms Control and Non-Proliferation in Washington, DC. He has published widely on issues related to the proliferation of nuclear, biological, and chemical weapons and has briefed the UN Security Council on the threat of non-state actors acquiring and using weapons of mass destruction.
“We are very enthusiastic about our efforts in the biodefense space,” added Wolf. “Our Biothreat Advisory Board brings deep insight and relationships that we expect will be instrumental in advancing our new biothreat initiatives. We look forward to providing more details as developments unfold.”
About Heat Biologics, Inc.
Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. Heat’s gp96 platform is designed to activate immune responses against cancer or infectious diseases. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in its Phase 2 trial, various infectious disease/biological threat programs in preclinical development and a pipeline of proprietary immunomodulatory antibodies and cell-based therapies, including PTX-35 and HS-130 in Phase 1 clinical trials.
For more information, please visit: https://www.heatbio.com, and also follow us on Twitter.
Forward Looking Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 on our current expectations and projections about future events. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectation, and assumptions and include statements regarding the contributions to be made by the advisory board, the Board bringing deep insight and relationships that will be instrumental in advancing our new biothreat initiatives and providing more details as developments unfold. These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, including the ability of Heat to successfully develop a new biosecurity/biodefense initiative and benefit from the contributions of the advisory board, the ability of Heat's therapies to perform as designed, to demonstrate safety and efficacy, as well as results that are consistent with prior results, the ability to enroll patients and complete the clinical trials on time and achieve desired results and benefits, especially in light of COVID-19, Heat's ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to Heat's ability to promote or commercialize its product candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, Heat's ability to maintain its license agreements, the continued maintenance and growth of its patent estate, its ability to establish and maintain collaborations, its ability to obtain or maintain the capital or grants necessary to fund its research and development activities and its cash and short-term investments providing significant runway to fund Heat’s current clinical programs and further expand Heat’s therapeutic portfolio , its ability to continue to maintain its listing on the Nasdaq Capital Market and its ability to retain its key scientists or management personnel, and the other factors described in Heat's annual report on Form 10-K for the year ended December 31, 2020 filed with the SEC, and other subsequent filings with the SEC. The information in this release is provided only as of the date of this release, and Heat undertakes no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.
Media and Investor Relations Contact
David Waldman
+1 919 289 4017
mailto://investorrelations@heatbio.com
NEWS -- Plus Therapeutics Presents Data from Preclinical Study of Rhenium-186 Nanoliposome in Leptomeningeal Metastases and Plans for Further Evaluation with Upcoming Phase 1 Clinical Trial
AUSTIN, Texas, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today presented data from a preclinical study evaluating its lead investigational drug, Rhenium-186 Nanoliposome (186RNL), in the treatment of leptomeningeal metastases (LM), and presented plans for a Phase 1 clinical trial of 186RNL also in LM. The data and upcoming trial plans were presented in two electronic posters (ePosters) at the Third Annual Conference on Brain Metastases hosted by the Society for Neuro-Oncology (SNO), being held virtually August 19-20, 2021.
“Leptomeningeal metastases are a fatal complication of advanced cancer and despite affecting more than 110,000 people per year in the United States alone, there remains a significant lack of effective therapies to treat this devastating disease,” said Andrew J. Brenner, M.D., Ph.D., Professor of Medicine, Neurology, and Neurosurgery at The University of Texas, and presenter of both ePosters. “Given our promising clinical experience thus far using 186RNL in recurrent glioblastoma, we are optimistic about the potential safety and efficacy for 186RNL as a novel treatment option for other central nervous system diseases like leptomeningeal metastases and certain pediatric brain cancers.”
Data from the ePoster entitled “Preclinical safety and activity of intraventricular Rhenium-186 Nanoliposome (186RNL) for leptomeningeal metastases” demonstrated that, following five different doses of 186RNL tested in non-tumor bearing rats administered with the highest doses (1.340mCi and 1.15mCi) presented minimal weight loss the first week after surgery, but gained it back in subsequent weeks and showed no overt neurological symptoms through the evaluation.
These results suggest that the maximum tolerable dose of 186RNL was not reached, and given the encouraging efficacy shown in pre-clinical LM models, 186RNL has the potential to provide high therapeutic doses for LM with low rates of toxicity.
Additional key findings include:
NEWS -- Heat Biologics Announces Formation of Biothreat Advisory Board
NEWS -- FuelPositive Commissions Study that shows Canada produces enough excess green energy today to replace fossil fuels used for freight transportation, passenger aviation and more with carbon-free ammonia (NH3)
TORONTO, Aug 17, 2021 (GLOBE NEWSWIRE via COMTEX) -- TORONTO, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Canada produces sufficient green electricity in off-peak demand hours to produce enough carbon-free ammonia (NH3) to replace the use of fossil fuels for 100% of the passenger and freight aviation and rail, passenger bus, freight trucking, freight rail and freight marine shipping in the country, according to a study commissioned by FuelPositive Corporation (TSX.V: NHHH) (OTCQB: NHHHF) ("FuelPositive" or the "Company"). If all carbon-free ammonia were used, the result would be a 15.3% reduction in Canada's total greenhouse gas emissions. [Link to study summary: http://ml.globenewswire.com/Resource/Download/5ee10c6a-ba72-409f-bc0c-be756681fae9]
In early 2021, FuelPositive commissioned emissions reduction and carbon credit specialist Andre Mech to conduct an analysis of Canada's green off-peak electricity capacity and to determine the fuel needs and the carbon emissions of the Canadian transportation sector. The intention was to discover whether it would be possible to replace fossil fuels used for transportation with carbon-free ammonia (NH3) - and to measure the impact that would have on the country's carbon emissions. FuelPositive's carbon-free NH3 is produced using only air, water and green electricity. For the purposes of this study, Mech used 2019 data. Green electricity was defined as hydroelectric, solar and wind.
The findings of Mech's analysis were startling. Canada has enough off-peak green electricity today to provide non-polluting, carbon-free NH3 fuel to power 63% of all the passenger cars, light trucks, passenger aviation, buses, light rail, motorcycles, freight trucking, freight aviation, rail, marine and other sector vehicles in the country. But even more exciting, Canada has enough off-peak green electricity to provide carbon-free NH3 to power 100% of the needs of passenger and freight aviation and rail, passenger bus, freight trucking, freight rail and freight marine shipping in Canada - all regulated industries that are notoriously high greenhouse gas emitters with significant government mandates to decarbonize.
"Switching from fossil fuels to carbon-free ammonia offers a viable, economical transition strategy for Canada's transportation sector as we adopt new practices to address climate change," said Ian Clifford, FuelPositive CEO. "Many people don't know it, but planes, trains, ships, trucks and other vehicles can be converted to run on ammonia - just as easily as they can be converted from gasoline and diesel to run on propane. The transportation sector just didn't see a benefit to switching to ammonia until now, because the production of traditional ammonia results in massive carbon emissions. But, when you use our carbon-free NH3 made from green electricity rather than traditional ammonia, it means we can move people around and transport goods with no pollution."
"The analysis outlines the opportunities and needs at the provincial and territorial levels," said study author Andre Mech. Three provinces - Manitoba, Quebec and Newfoundland & Labrador - already generate enough renewable electricity to cover their passenger aviation, passenger rail and freight transportation fuel requirements using FuelPositive's carbon-free NH3 system. In a national strategy, they would be green ammonia suppliers. The remaining provinces and territories would be green ammonia consumers. According to Mech: "The good news is that there are suppliers and consumers. That tells us that there is a market for green ammonia within Canada itself."
Grid Storage
Interestingly, the analysis also points out that the three provinces can also store their excess renewable electricity for later use, by running FuelPositive's commercial modular and scalable carbon-free NH3 production systems on site. The problem with renewables in the past was that there was no viable and scalable excess energy storage mechanism. FuelPositive has developed a patent-pending system to economically produce and store carbon-free ammonia from air, water and sustainable electricity - wherever it is needed, whenever it is needed. During periods of peak demand, even when there is no wind for windmills or sun for solar panels, the extra carbon-free NH3 stored on site can be combusted in NH3-burning turbines to generate and distribute electricity to meet demand. [link to Grid Storage: https://fuelpositive.com/our-carbon-free-grid-storage/]
About Andre Mech
Andre Mech has been advising organizations and governments focused on sustainability, energy efficiency and carbon reduction worldwide since 2001 - most recently in North America and Europe. As one of the most knowledgeable emissions reduction and carbon credit specialists in the sector, he has assessed the emission profiles of hundreds of technologies. Mech formally joined FuelPositive as a Strategic Advisor in July 2021.
About Fuel Positive
FuelPositive is a Canadian growth-stage technology company committed to providing commercially viable and sustainable, "cradle to cradle", clean energy solutions, including carbon-free ammonia (NH3), for use across a broad spectrum of industries and applications. By focusing on technologies that are clean, economically advantageous/ realizable and that leverage existing infrastructure, the Company aims to change the course of climate change through practical solutions that can be implemented now.
Cautionary Statement
Trading in the securities of the Company should be considered highly speculative. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains certain "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") that are based on expectations, estimates and projections as at the date of this news release. The information in this release about future plans and objectives of the Company are forward-looking statements.
These forward-looking statements are based on assumptions and estimates of management of the Company at the time they were made and involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect.
Many of these uncertainties and contingencies can directly or indirectly affect actual results and could cause actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
Forward-looking information is provided for the purpose of providing information about management's expectations and plans relating to the future. The Company disclaims any intention or obligation to update or revise any forward-looking information or to explain any material difference between subsequent actual events and such forward-looking information, except to the extent required by applicable law.
For Media or Investor enquiries, please contact:
Ian Clifford
FuelPositive Chief Executive Officer
mailto://investors@fuelpositive.com
https://www.fuelpositive.com
Investor Relations (U.S.):
RBMG - RB Milestone Group LLC
Trevor Brucato, Managing Director
mailto://fuelpositive@rbmilestone.com
https://www.rbmilestone.com
Corporate Communications:
InvestorBrandNetwork (IBN)
Los Angeles, CA
https://www.IBN.fm
310.299.1717 Office
mailto://Editor@NetworkNewsWire.com
Government Relations:
Sussex Strategy Group
Toronto & Ottawa
https://www.sussex-strategy.com/
Contact: Devin McCarthy
(613) 864-0263
mailto://dmccarthy@sussex-strategy.com
A summary report associated with this press release is available at: http://ml.globenewswire.com/Resource/Download/5ee10c6a-ba72-409f-bc0c-be756681fae9
NEW CEO of VNTH Is Frank Ikechukwu Igwealor ,look what he did with NIHK,DRNG,GMPW . He brings good things to life and money !!!
WWW. Video River full of money .com
NEWS -- Plus Therapeutics to Present Data from ReSPECT™-GBM Trial at the American Association of Neurological Surgeons 2021 Annual Scientific Meeting
AUSTIN, Texas, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted therapies for rare and difficult-to-treat cancers, today announced it will present data on Rhenium-186 NanoLiposome (186RNL) from its Phase 1 ReSPECT™ clinical trial in recurrent glioblastoma (GBM) at the American Association of Neurological Surgeons 2021 Annual Scientific Meeting (AANS) being held virtually August 21-25, 2021.
Details of the ePoster presentation are as follows:
Title:
NEWS -- Second U.S. FDA Breakthrough Device Designation Granted to CytoSorbents' DrugSorb-ATR™ Antithrombotic Removal System Adding the Removal of Market-Leading Direct Oral Anticoagulants During Urgent Cardiothoracic Surgery
MONMOUTH JUNCTION, N.J., Aug. 12, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that the Company has been granted a second Breakthrough Device designation for its DrugSorb-ATR Antithrombotic Removal System by the U.S. Food and Drug Administration (FDA). This Breakthrough Device designation covers the removal of the Direct Oral Anticoagulants (DOACs) apixaban and rivaroxaban in a cardiopulmonary bypass circuit to reduce the likelihood of serious perioperative bleeding in urgent cardiothoracic surgery. It follows the Breakthrough Designation received in April 2020 to remove ticagrelor for the same application.
Dr. David Cox, Vice President of Global Regulatory Affairs of CytoSorbents remarked, "The U.S. Prescribing Information for apixaban and rivaroxaban, two leading DOACs taken to reduce the risk of blood clots and associated complications, clearly warns that dosing should be stopped prior to a surgical procedure to reduce the risk of bleeding. Unfortunately, in unexpected urgent cardiothoracic surgery, this is often not possible, posing the risk of life-threatening bleeding in these patients. We are pleased that the FDA has recognized the potential of our DrugSorb-ATR Antithrombotic Removal System to reduce levels of these drugs in a patient's blood, potentially decreasing the risk of life-threatening perioperative bleeding. The achievement of two Breakthrough Designations in these situations where no approved or cleared alternatives exist is a major Company milestone that is expected to expedite our regulatory and clinical goals."
Mr. Vincent Capponi, President and Chief Operating Officer of CytoSorbents stated, "We are pleased that the DrugSorb-ATR Antithrombotic Removal System has been granted a second Breakthrough Device designation by the FDA. With this achievement, we continue to execute upon our multi-phase U.S. strategy to potentially establish DrugSorb-ATR as an easy-to-implement, new standard of care to remove antithrombotic drugs during cardiothoracic surgery. The U.S. STAR-T (Safe and Timely Antithrombotic Removal - Ticagrelor) pivotal randomized, controlled clinical trial is now underway and we look forward to working with the FDA in pursuit of the next IDE approval for the U.S. study on DOAC removal during cardiothoracic surgery. We estimate the total addressable market for DrugSorb-ATR to remove ticagrelor, apixaban, and rivaroxaban during cardiothoracic surgery is more than $500 million in the U.S. alone today, which is expected to significantly increase based on prescribing trends and generic availability of these drugs."
Apixaban (Eliquis®, Bristol Myers Squibb/Pfizer) and rivaroxaban (Xarelto®, Jansen/Johnson & Johnson) are two of the most commonly prescribed anticoagulants worldwide, including more than 5 million patients1 annually in the United States who are chronically on these medications to reduce the risk of deadly blood clots due to atrial fibrillation, prior history of heart attack or stroke, deep vein thrombosis, pulmonary embolism, and peripheral artery disease. We expect the number of patients prescribed these drugs to continue to climb based on the superior performance of these agents compared to older alternatives, underlying demographic trends in the aging baby boomer population, improved disease detection rates, and other factors. When patients on various "blood thinners", like apixaban or rivaroxaban, require urgent cardiothoracic surgery, the risk of serious or life-threatening bleeding and complications is very high. Based on our estimates, at least 1% of patients in the U.S. on apixaban or rivaroxaban may require urgent cardiothoracic surgery on an annual basis. Today there are no approved or cleared alternatives in the U.S. to reduce bleeding risks during cardiothoracic surgery caused by direct oral anticoagulants. DrugSorb-ATR has the potential to address this major unmet medical need.
About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification. Its flagship product, CytoSorb®, is approved in the European Union with distribution in 68 countries around the world as an extracorporeal cytokine adsorber designed to reduce the "cytokine storm" or "cytokine release syndrome" seen in common critical illnesses that may result in massive inflammation, organ failure and patient death. These are conditions where the risk of death can be extremely high, yet few to no effective treatments exist. CytoSorb is also being used during and after cardiothoracic surgery to remove inflammatory mediators that can lead to post-operative complications, including multiple organ failure. More than 143,000 CytoSorb devices have been delivered to date. CytoSorb was originally introduced into the European Union under CE-Mark as a first-in-kind cytokine adsorber. Additional CE-Mark label expansions were received for the removal of bilirubin and myoglobin in clinical conditions such as liver disease and trauma, respectively, and both ticagrelor and rivaroxaban during cardiothoracic surgery. CytoSorb has also received FDA Emergency Use Authorization in the United States for use in critically ill COVID-19 patients with imminent or confirmed respiratory failure. CytoSorbents' technology has also been granted FDA Breakthrough Designation for the removal of ticagrelor, rivaroxaban, and apixaban in a cardiopulmonary bypass circuit during urgent cardiothoracic surgery, and if FDA marketing approval is obtained, would be marketed as DrugSorb-ATR™ in the United States.
CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of more than $39.5 million from DARPA, the U.S. Department of Health and Human Services (HHS), the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), the U.S. Army, the U.S. Air Force, U.S. Special Operations Command (SOCOM), Air Force Material Command (USAF/AFMC), and others. The Company has numerous marketed products and products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and registered trademarks, and multiple patent applications pending, including ECOS-300CY®, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™, DrugSorb™, DrugSorb-ATR™, ContrastSorb, and others. For more information, please visit the Company's websites at https://www.cytosorbents.com and https://www.cytosorb.com or follow us on Facebook and Twitter.
Forward-Looking Statements
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, anticipated future results and performance, representations and contentions and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 9, 2021, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.
Investor Relations Contact:
Terri Anne Powers
Vice President, Investor Relations and Corporate Communications
(732) 482-9984
mailto:?/tpowers@cytosorbents.com
U.S. Public Relations Contact:
Eric Kim
Rubenstein Public Relations
212-805-3052
mailto://ekim@rubensteinpr.com
1 Agency for Healthcare Research and Quality. Number of people with purchase in thousands by prescribed drug, United States, 1996-2018. Medical Expenditure Panel Survey. Generated interactively May 27, 2021. CytoSorbents estimates.
View original content to download multimedia: https://www.prnewswire.com/news-releases/second-us-fda-breakthrough-device-designation-granted-to-cytosorbents-drugsorb-atr-antithrombotic-removal-system-adding-the-removal-of-market-leading-direct-oral-anticoagulants-during-urgent-cardiothoracic-surgery-301354007.html
SOURCE CytoSorbents Corporation
NEWS -- Lineage Reports Second Quarter 2021 Financial Results and Highlights Additional Progress From Clinical Cell Therapy Programs
Here is the SEC's Notice of Effectiveness for $GMPW's S-1. Congratulations to all our patient shareholders and the family of $NIHK and $DRNG, as we move to remove the CE and then proceed to implement our business plan as articulated in our S-1. See. https://t.co/ONTARtKgw8 pic.twitter.com/t4YZxzT99k
— GiveMePower (@GiveMePower5) August 12, 2021
In the next two weeks if you buy NIHK you will receive for every share you buy, you will get an equal share of DRNG .
The ones I have found are, NIHK ,DRNG ,VNTH, GMPW , any others?
Look at GMPW, once our CEO got there it skyrocketed.
NEWS -- Last Patient Last Visit Completed in Innovation Pharmaceuticals’ Phase 2 Clinical Trial of Brilacidin for COVID-19; Trial Database Undergoing Review in Preparation for Database Lock
WAKEFIELD, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today provided additional information regarding the status of its randomized, double-blind, placebo-controlled Phase 2 clinical trial of Brilacidin for the treatment of moderate-to-severe COVID-19 in hospitalized patients (see NCT04784897). The Company is developing Brilacidin for treatment of COVID-19 under U.S. FDA Fast Track designation.
Full enrollment in the 120-patient clinical trial was completed in early June 2021. The last patient follow-up visit occurred on July 30, 2021. The subject database remains blinded with the current emphasis on confirmation of all data entered at study sites, as well as completion of source data verification and the necessary checks and reviews by the data management vendor in preparation of database lock.
Following database lock and transfer to the biostatistics vendor, analysis of the unblinded data from the clinical trial will begin to assess Brilacidin’s performance, against placebo, across primary, secondary, and other endpoints. Topline results are anticipated to be available one week after database lock, with full analysis to follow.
“Our team is as excited as anyone to learn the results of our Brilacidin COVID-19 clinical trial. Everything is advancing per industry norms and standards,” said Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “We look forward to sharing Brilacidin topline data in treating COVID-19 as soon as we have it in hand.”
About Brilacidin and COVID-19
Brilacidin is the only non-peptidic defensin-mimetic drug candidate currently in a clinical trial as a treatment for SARS-CoV-2, the coronavirus responsible for COVID-19 (see NCT04784897). Brilacidin has shown potent and consistent inhibition in vitro against coronaviruses, alphaviruses and bunyaviruses (with laboratory testing against other viruses also underway), supporting Brilacidin’s potential to be developed as a broad-spectrum antiviral. The annual global antiviral drug market is estimated to reach $44 billion by 2026.
A peer-reviewed article in Viruses supporting Brilacidin’s COVID-19 treatment potential can be accessed at the link below.
nihk CEO is now the CEO of VNTH , he keeps on collecting companies .
NEWS -- Heat Biologics Provides Second Quarter 2021 Business Update
DURHAM, N.C., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today provided financial, clinical and operational updates for the second quarter ended June 30, 2021.
Jeff Wolf, Chief Executive Officer of Heat, commented, “This quarter we achieved several meaningful clinical, research and business milestones. First, we presented favorable survival data of HS-110 in previously treated non-small cell lung cancer (NSCLC) patients at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. Based on these results, we believe HS-110, in combination with a checkpoint inhibitor (CPI), holds significant potential to improve survival benefit for patients with non-small cell lung cancer. We are continuing to evaluate possible Phase 3 registration pathways with the FDA and potential partners. At the same time, we are exploring a variety of paths forward related to our infectious disease efforts. We look forward to providing further near-term updates.”
“This quarter we also announced the groundbreaking for our biomanufacturing/bioanalytic facility in San Antonio, TX and the expansion of our current research and development (R&D) facilities at our corporate headquarters in Morrisville, NC. This expansion will support enhanced R&D capabilities including in-house synthesis and production of antibodies and other drugs/reagents, as well as an expanded vivarium for onsite pre-clinical studies. We believe that this expansion will allow us to accelerate R&D timelines and generate cost savings on research and development by bringing more of our development activities in-house.”
“Moreover, we have maintained a strong balance sheet with approximately $122.5 million of cash, cash equivalents and short-term investments which should allow us to augment our clinical programs as well as enhance and expand our therapeutic pipeline.”
Second Quarter 2021 Financial Results
NEWS -- Navidea Biopharmaceuticals Reports Second Quarter 2021 Financial Results
Conference Call to be held Wednesday, August 11, 2021 at 5:00 pm EDT
DUBLIN, Ohio, August 11, 2021--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the second quarter and year-to-date for the period ended June 30, 2021.
"The Company is prepared and looking forward to our meeting with the U.S. Food and Drug Administration ("FDA") on September 1," said Mr. Jed A. Latkin, Chief Executive Officer of Navidea. "We remain laser focused on a positive meeting and a successful launch to the NAV3-33 trial. Navidea is also extremely excited to now have a full 7-member board with the appointments of Amit Bhalla, Alex Cappello and John K. Scott, Jr. to the board."
Second Quarter 2021 Highlights and Subsequent Events
NEWS -- Video River Networks & its Subsidiary Drone Guarder Announce Special One-time Dividend
TORRANCE, Calif., Aug. 11, 2021 /PRNewswire/ -- Drone Guarder, Inc. (OTC: DRNG) has announced a special one-time dividend of 439,097,990 shares of its stock payable to both common and preferred stockholders. Stockholders of common stock will receive 1 additional share of DRNG for every 10 shares owned. Common stockholders would receive a total of 261,175,554 shares, and Preferred stockholders would receive a total of 177,922,436 shares.
With this special dividend, Drone Guarder is rewarding its common and preferred shareholders for their diligence as the company pursued a restructuring program designed to unburden itself from the decisions of its previous management. Drone Guarder was recently acquired by Video River Networks and is in the process of becoming current with OTC Market regulations. The company's new CEO Frank Igwealor said, "We believe it is productive to reward faithful and loyal shareholders with additional shares of the company at this time."
Video River Networks (OTC:NIHK), has also authorized the redistribution of the dividends it would receive from DRNG directly to its stockholders. The company will redistribute shares received from DRNG to its shareholders at a ratio of 1 share of DRNG for each share of NIHK held.
Its CEO added, "Our new structure will provide Drone Guarder with the financial flexibility to make opportunistic acquisitions and share repurchases, while we organically grow our drone and AI businesses through acquisitions that meet target return thresholds."
Both companies' dividends are payable on or after September 30th, 2021, to shareholders of record at the close of business on August 31, 2021.
About Video River Networks, Inc.
Video River Networks, Inc. is an Electric Vehicles and Battery Technology holding company that operates and manages a portfolio of Electric Vehicles, Artificial Intelligence, Machine Learning and Robotics ("EV-AI-ML-R") assets, businesses and operations in North America. The Company's current and target portfolio businesses and assets include operations that design, develop, manufacture and sell high-performance fully electric vehicles and design, manufacture, install and sell Power Controls, Battery Technology, Wireless Technology, and Residential utility meters and remote, mission-critical devices mostly engineered through Artificial Intelligence, Machine Learning and Robotic technologies. NIHK's current technology-focused business model is a result of our board resolution on September 15, 2020 to spin-in/off our specialty real estate holding business to an operating subsidiary and then pivot back to being a technology company. The Company has now returned back to its original technology-focused businesses of Power Controls, Battery Technology, Wireless Technology, and Residential utility meters and remote, mission-critical devices. For more information and the latest updates check the company's Twitter account at https://twitter.com/NIHKEV
CONTACT:
Video River Networks, Inc.
370 Amapola Ave., Suite 200A
Torrance, CA 90501
contact@videorivernetworks.net
View original content: https://www.prnewswire.com/news-releases/video-river-networks--its-subsidiary-drone-guarder-announce-special-one-time-dividend-301353386.html
SOURCE Video River Networks
NEWS -- Video River Networks & its Subsidiary Drone Guarder Announce Special One-time Dividend
TORRANCE, Calif., Aug. 11, 2021 /PRNewswire/ -- Drone Guarder, Inc. (OTC: DRNG) has announced a special one-time dividend of 439,097,990 shares of its stock payable to both common and preferred stockholders. Stockholders of common stock will receive 1 additional share of DRNG for every 10 shares owned. Common stockholders would receive a total of 261,175,554 shares, and Preferred stockholders would receive a total of 177,922,436 shares.
With this special dividend, Drone Guarder is rewarding its common and preferred shareholders for their diligence as the company pursued a restructuring program designed to unburden itself from the decisions of its previous management. Drone Guarder was recently acquired by Video River Networks and is in the process of becoming current with OTC Market regulations. The company's new CEO Frank Igwealor said, "We believe it is productive to reward faithful and loyal shareholders with additional shares of the company at this time."
Video River Networks (OTC:NIHK), has also authorized the redistribution of the dividends it would receive from DRNG directly to its stockholders. The company will redistribute shares received from DRNG to its shareholders at a ratio of 1 share of DRNG for each share of NIHK held.
Its CEO added, "Our new structure will provide Drone Guarder with the financial flexibility to make opportunistic acquisitions and share repurchases, while we organically grow our drone and AI businesses through acquisitions that meet target return thresholds."
Both companies' dividends are payable on or after September 30th, 2021, to shareholders of record at the close of business on August 31, 2021.
About Video River Networks, Inc.
Video River Networks, Inc. is an Electric Vehicles and Battery Technology holding company that operates and manages a portfolio of Electric Vehicles, Artificial Intelligence, Machine Learning and Robotics ("EV-AI-ML-R") assets, businesses and operations in North America. The Company's current and target portfolio businesses and assets include operations that design, develop, manufacture and sell high-performance fully electric vehicles and design, manufacture, install and sell Power Controls, Battery Technology, Wireless Technology, and Residential utility meters and remote, mission-critical devices mostly engineered through Artificial Intelligence, Machine Learning and Robotic technologies. NIHK's current technology-focused business model is a result of our board resolution on September 15, 2020 to spin-in/off our specialty real estate holding business to an operating subsidiary and then pivot back to being a technology company. The Company has now returned back to its original technology-focused businesses of Power Controls, Battery Technology, Wireless Technology, and Residential utility meters and remote, mission-critical devices. For more information and the latest updates check the company's Twitter account at https://twitter.com/NIHKEV
CONTACT:
Video River Networks, Inc.
370 Amapola Ave., Suite 200A
Torrance, CA 90501
contact@videorivernetworks.net
View original content: https://www.prnewswire.com/news-releases/video-river-networks--its-subsidiary-drone-guarder-announce-special-one-time-dividend-301353386.html
SOURCE Video River Networks
NEWS -- Plus Therapeutics to Present Data from Two Studies Supporting the Treatment of Leptomeningeal Metastases with Rhenium-186 Nanoliposome
AUSTIN, Texas, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted therapies for rare and difficult to treat cancers, today announced it will present data from one planned clinical trial and one completed preclinical study evaluating its lead investigational drug, Rhenium-186 Nanoliposome (186RNL), for the treatment of leptomeningeal metastases (LM). The data will be presented at the Third Annual Conference on Brain Metastases hosted by the Society for Neuro-Oncology (SNO), being held virtually August 19-20, 2021.
Data from both studies will be presented as electronic posters (ePosters) by Andrew J. Brenner, M.D., Ph.D., Associate Professor of Medicine, Neurology, and Neurosurgery at The University of Texas, and principal investigator, and will be viewable to meeting attendees beginning at the start of the conference on Thursday, August 19 at 11:00 am EDT. The accepted abstracts are currently available in the Neuro-Oncology Advances Journal. Details of both are as follows:
LMD-13: “ReSPECT™-LM: Maximum tolerated dose, safety, and efficacy of intraventricular Rhenium-186 Nanoliposome (186RNL) for leptomeningeal metastases”
Data from the ongoing U.S. multi-center ReSPECT-GBM Phase 1 dose-finding clinical trial in adults with recurrent glioblastoma (NCT01906385) demonstrate that the mean absorbed dose of 186RNL to the tumor when coverage was 75% or greater (n=10) was 392 Gy (CI 306 – 478). Thus far, the therapy has been well tolerated with one possible treatment-related serious adverse event, cerebral edema, that resolved after steroid treatment.
In addition, this abstract details a proposed two-part clinical trial for patients with leptomeningeal metastases (LM). Part 1 will enroll up to 21 subjects to characterize the safety and tolerability of a single dose of 186RNL administered intraventricularly via an Ommaya reservoir and identify a maximum tolerated dose (MTD) / maximum feasible dose (MFD) for future studies, and Part 2 will independently evaluate 186RNL in two different cohorts. Cohort A will enroll up to 20 subjects with a diagnosis of LM from primary breast cancer. Cohort B will enroll up to 20 subjects with a diagnosis of LM from primary non-small cell lung cancer. The primary endpoint is to estimate the anti-tumor activity of 186RNL as a single agent. The full abstract can be found here: https://academic.oup.com/noa/article/3/Supplement_3/iii10/6345010.
LMD-14: “Preclinical safety and activity of intraventricular Rhenium-186 Nanoliposome (186RNL) for leptomeningeal metastases”
As part of this preclinical safety and activity study, researchers concluded that the intraventricular delivery of 186RNL is well tolerated and improves animal survival at two weeks in a rat model of LM. The full abstract can be found here: https://academic.oup.com/noa/article/3/Supplement_3/iii10/6345068.
Copies of each poster will be made available under the Presentations tab of the Investors section of the Company’s website when presentations go live at https://www.plustherapeutics.com.
LM are a rare but typically fatal complication of advanced cancer that affects the fluid-lined structures of the central nervous system and are diagnosed in approximately five percent of patients with metastatic cancer. With survival measured in weeks to months, novel approaches are needed that can both improve quality and quantity of life. 186RNL permits the selective delivery of beta-emitting radiation of high specific activity directly to the tumor.
About Plus Therapeutics, Inc.
Plus Therapeutics (Nasdaq: PSTV) is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets. Central to the Company’s drug development is a unique nanotechnology platform designed to reformulate, deliver and commercialize multiple drugs targeting rare cancers and other diseases. The platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers. More information may be found at https://PlusTherapeutics.com and https://ReSPECT-Trials.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “will,” “believe,” “plan,” “can,” “enable,” “design,” “intend,” “potential,” “expect,” “estimate,” “project,” “prospect,” “target,” “focus,” “anticipate,” “could,” “should,” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the design and potential of the Plus Therapeutics portfolio to reformulate, deliver and commercialize multiple novel, proprietary drugs targeting rare cancers and other diseases and to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs; the potential of the Company’s in-licensed portfolio of investigational drugs; the Company’s intent to advance its CNS oncology portfolio through the clinical development process; the ability of RNL to safely, effectively and conveniently deliver a very high dose of radiation directly into the brain tumor; anticipated benefits of strategic collaborations and license agreements, intellectual property, FDA approval process and government regulation; and the Company’s anticipated milestones and events, including with respect to additional sites, enrollment, pivotal trial planning, IND process, and clinical phase plans for RNL, pipeline expansion through additional drug development candidates, and partnership discussions for RNL, DocePLUS and DoxoPLUS; and future development and/or expansion of its product candidates and therapies in its markets. The forward-looking statements included in this press release are subject to a number of risks and uncertainties that may cause actual results to differ materially from those discussed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that the Company is not able to successfully develop product candidates that can leverage the FDA’s accelerated regulatory pathways; the early stage of the Company’s product candidates and therapies, the results of its research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s history of losses; the Company’s need for, and ability to raise, additional cash or obtain other sources of funding in the immediate future; the Company’s ability to: (a) obtain and maintain regulatory approvals, (b) continue as a going concern, (c) remain listed on the Nasdaq Capital Market, (d) to obtain or maintain sufficient levels of reimbursement for its tests, and (d) to repay or refinance some or all of its outstanding indebtedness; the outcome of the Company’s partnering/licensing efforts; market and economic conditions; the impact of the COVID-19 pandemic on the Company and the effectiveness of the efforts it has taken or may take in the future in response thereto; and additional risks described under the heading “Risk Factors” in the Company’s Securities and Exchange Commission filings, including in the Company’s annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.
Investor Contact
Peter Vozzo
Westwicke/ICR
(443) 377-4767
mailto://Peter.Vozzo@westwicke.com
Media Contact
Terri Clevenger
Westwicke/ICR
(203) 856-4326
mailto://Terri.Clevenger@westwicke.com
The next step is the cancelation of the 100 billion OS . The CEO did the same for DRNG !
He is a shorter , I think when the website is activated you will be able to see the info on the dividend .
NEWS -- Lineage to Present at the H.C. Wainwright Ophthalmology Conference on August 17, 2021
CARLSBAD, Calif., August 10, 2021--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, the Company’s Chief Executive Officer, will be participating in and presenting at the H.C. Wainwright & Co. Inc. Virtual Ophthalmology Conference (https://hcwevents.com/ophthalmologyconference/). Mr. Culley’s presentation will be available on-demand starting on August 17th, 2021 at 7am ET / 4am PT. Mr. Culley will also participate in an industry panel, Addressing Unmet Medical Needs in Macular Degeneration – Dry AMD and Stargardt Disease, hosted by Yi Chen, Ph.D., CFA, Managing Director, Senior Healthcare Analyst, H.C. Wainwright & Co., Inc., on August 17th, 2021 at 11am ET / 8am PT.
Interested parties can register to view both the on-demand and live industry panel presentations on the Events and Presentations section (https://investor.lineagecell.com/events-and-presentations/upcoming-events) of Lineage’s website. Additional videos are available on the Media page (https://lineagecell.com/media/) of the Lineage website.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include three allogeneic ("off-the-shelf") product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of subacute spinal cord injuries; and (iii) VAC2, an allogeneic dendritic cell therapy produced from Lineage’s VAC technology platform for immuno-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer. For more information, please visit https://www.lineagecell.com or follow the Company on Twitter @LineageCell.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210810005334/en/
Contacts
Lineage Cell Therapeutics, Inc. IR
Ioana C. Hone
(mailto://ir@lineagecell.com)
(442) 287-8963
Solebury Trout IR
Gitanjali Jain Ogawa
(mailto://Gogawa@soleburytrout.com)
(646) 378-2949
Russo Partners – Media Relations
Nic Johnson or David Schull
mailto://Nic.johnson@russopartnersllc.com
mailto://David.schull@russopartnersllc.com
(212) 845-4242